Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
Cardiovascular disease (CVD) remains the major cause of mortality and morbidity in both type
1 (T1D) and type 2 (T2D) diabetes patients; modifications of traditional CVD risk factors
have had a limited impact. This project called Regadenoson Blood flow in Type 1 Diabetes
(RABIT1D) and is proposed as a sub-study of the Coronary Artery Calcification in Type 1
Diabetes (CACTI) study, which has established a unique cohort of 656 T1D patients (age 20-55,
minimal diabetes duration of 10 yrs) and 764 non-diabetic controls. This cohort is being
followed for progression of coronary artery calcification (CAC) measured using the electron
beam tomography (EBT) for development of clinical CVD. Participants have been well
characterized during the baseline examination (4/00-3/02) and two follow-up re-examinations 3
and 6 years later. The study has provided important insights into the risk factors and
possible prevention of premature CVD in T1D. We are proposing assess a subset of this
population to determine vasodilatory reserve as it relates to early coronary atherosclerosis
in T1D.
Hypothesis: that myocardial blood imaging (MBF) reserve can be measured in Type 1 diabetes
mellitus (DM) using regadenoson stress cardiac magnetic resonance and that significantly
reduced MBF is a marker of extensive atherosclerotic disease correlated to coronary arterial
calcification, plaque formation and impaired vasodilatory reserve.